With the promise of T cell-based therapy for cancer finally becoming reality, this Review
focuses on the less-studied γδ T cell lineage and its diverse responses to tumours. γδ T cells …

Cancers are not just masses of malignant cells but complex 'rogue'organs, to which many
other cells are recruited and can be corrupted by the transformed cells. Interactions between …

Although immune checkpoint inhibitors (ICIs) that target programmed cell death protein-
1/programmed cell death ligand-1 axis have significantly shifted the treatment paradigm in …

T lymphocytes comprise cells expressing either an αβ or a γδ TCR. The riddle how αβ TCRs
are triggered by specific peptides presented in the context of MHC was elucidated some …

Adoptive cellular immunotherapy (ACT) employing engineered T lymphocytes expressing
chimeric antigen receptors (CARs) has demonstrated promising antitumor effects in …

The role of IL-17 in cancer remains controversial. Emerging evidence suggests that during
early oncogenesis IL-17 supports tumor growth, whereas in established tumors IL-17 …

Cancer-associated inflammation mobilizes a variety of leukocyte populations that can inhibit
or enhance tumor cell growth in situ. These subsets include γδ T cells, which can infiltrate …

Lung cancer, the leading cause of cancer-related deaths worldwide, is a heterogeneous
disease comprising multiple histologic subtypes that harbor disparate mutational profiles …

The tumor immune microenvironment contributes to tumor initiation, progression, and
response to therapy. Among the immune cell subsets that play a role in the tumor …

Despite conventional treatment modalities, gallbladder cancer (GBC) remains a highly lethal
malignancy. Prognostic biomarkers and effective adjuvant immunotherapy for GBC are not …